Statement of the American society of addiction medicine consensus panel on the use of buprenorphine in office-based treatment of opioid addiction

Journal of Addiction Medicine

Volumn 5, Issue 4, 2011, Pages 254-263

  Kraus, Mark L ^a,b,c   Alford, Daniel P ^d,e   Kotz, Margaret M ^f,g   Levounis, Petros ^h,i,j   Mandell, Todd W ^k   Meyer, Marjorie ^l,m   Salsitz, Edwin A ⁿ   Wetterau, Norman ^o   Wyatt, Stephen A ^p  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Westside Medical Group PC   (United States)

^c Connecticut Counseling Centers ^*  (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON MEDICAL CENTER   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h Addiction Institute of New York   (United States)

ⁱ Hospital Israelita Albert Einstein   (United States)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k Community Substance Abuse Centers Inc ^*  (United States)

^l Opiate Treatment Program During Pregnancy   (United States)

^m UNIVERSITY OF VERMONT   (United States)

ⁿ BETH ISRAEL MEDICAL CENTER   (United States)

^o Tri County Family Medicine   (United States)

^p MIDDLESEX HOSPITAL   (United States)

more..

Author keywords

Buprenorphine; Office based treatment; Opioid addiction

Indexed keywords

BUPRENORPHINE; METHADONE;

ARTICLE; BREAST FEEDING; CHRONIC PAIN; COMORBIDITY; CONSENSUS DEVELOPMENT; COPING BEHAVIOR; DETOXIFICATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE DELIVERY; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; NEEDS ASSESSMENT; OPIATE ADDICTION; PATIENT ASSESSMENT; PATIENT COUNSELING; PATIENT SELECTION; PREGNANT WOMAN; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PSYCHOLOGIC ASSESSMENT; TREATMENT OUTCOME;

AMBULATORY CARE; BUPRENORPHINE; COMORBIDITY; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; NALOXONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; RECURRENCE; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84856820708     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3182312983     Document Type: Article

References (53)

1. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy [Review]. Ann Intern Med 2006;144(2):127-134. (Pubitemid 46768231)
2. Erratum in Ann Intern Med 2006;144(6):460.
3. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2008a;(4):CD005031.
4. Update of Cochrane Database Syst Rev 2004 18;(4):CD005031.
5. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2008b; (4):CD004147.
6. Update of Cochrane Database Syst Rev 2004;(4):CD005031.
7. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28:321-329. (Pubitemid 40733141)
8. Anderson IB, Kearney TE. Use of methadone. West J Med 2000;172(1):43-46.
9. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34(1):188-193. (Pubitemid 32591499)
10. Batki SL, for the CSAT Consensus Panel. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs (Treatment Improvement Protocol [TIP] Series, Number 43). Rockville: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (DHHS Publication No. [SMA] 06-4214), 2005.
11. Baxter LE for the ASAM Methadone Action Group. Clinical Guidance on Methadone Induction and Stabilization. Chevy Chase: American Society of Addiction Medicine, Inc (in field review 2009).
12. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend 2008;94(1-3):38-47.
13. Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001;34:346-350. (Pubitemid 32176462)
14. Bio LL, Siu A, Poon CY. Update on the pharmacologicmanagement of neonatal abstinence syndrome. J Perinatol August 25, 2011 [epub ahead of print].
15. Blow F. Older adults. In: Graham AW, Schultz TK,Mayo-Smith MF, et al., eds. Principles of Addiction Medicine, Third Edition. Chevy Chase: American Society of Addiction Medicine, 2003.
16. Briggs GC, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, Eight Edition. Philadelphia: Lippincott Williams & Wilkins, 2008: 212-213.
17. Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction between buprenorphine and atazanavir plus ritonavir. AIDS 2006;20(5):783-784. (Pubitemid 43884310)
18. Caplehorn J, Deeks JJ. A critical appraisal of the Australian comparative trial of methadone and buprenorphine maintenance [Review]. Drug Alcohol Rev 2006;25(2):157-160. (Pubitemid 43688730)
19. Carrieri MP, Vlahov D, Dellamonica P, et al. Use of buprenorphine in HIV infected injection drug users: negligible impact on virological response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend 2000;60: 51-54. (Pubitemid 30255985)
20. Cazorla C, Grenier de Cardenal D, Schumacher H, et al. Infectious complications and misuse of high-dose buprenorphine. Presse Med 2005;34(10): 719-724. (Pubitemid 40868354)
21. Center for Substance Abuse Treatment. Substance Abuse: Administrative Issues in Outpatient Treatment (Treatment Improvement Protocol [TIP] 46). Rockville: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2006.
22. Center for Substance Abuse Treatment. The SAMHSA Evaluation of the Impact of the DATAWaiver Program: Summary Report. Rockville: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 30, 2006.
23. Collins GB, McAllister MS. Buprenorphine maintenance: a new treatment for opioid dependence. Cleve Clin J Med 2007;74(7):514-520.
24. Comer SD, Sullivan MA, Walker EA. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 2005;315(3): 1320-1330. (Pubitemid 41635421)
25. Comer SD, Walker EA, Collins ED. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology (Berl) 2005;181(4):664-675. (Pubitemid 41400752)
26. Connors GJ, Longabaugh R, Miller WR. Looking forward and back to relapse: implications for research and practice. Addiction 1996;91 (Suppl):S191-S196. (Pubitemid 27029848)
27. Daley DC, Salloum IM, Zuckoff A, Kirisci L, Thase ME. Increasing treatment adherence among outpatients with depression and cocaine dependence: results of a pilot study. Am J Psychiatry 1998;155(11):1611-1613. (Pubitemid 28512036)
28. Dashe JS, Sheffield JS, Wendel GD Jr. Improving the management of opioiddependent pregnancies. Am J Obstet Gynecol 2004;190(6):1806; author reply 1806-1807.
29. Dausey DJ, Desai RA. Psychiatric comorbidity and the prevalence of HIV infection in a sample of patients in treatment for substance abuse. J Nerv Ment Dis 2003;191(1):10-17. (Pubitemid 36133986)
30. Dimeff LA, Marlatt GA. Relapse prevention. In:Hester R, Miller W, eds. Handbook of Alcoholism Treatment Approaches, 2nd Edition. Boston: Allyn & Bacon, 1995:176-194.
31. Edge WG, Cooper GM, Morgan M. Analgesic effects of sublingual buprenorphine. Anaesthesia 1979;34(5):463-467. (Pubitemid 9193633)
32. Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med 2007;1(2):62-67.
33. Fiellin DA. Treatment of adolescent opioid dependence: no quick fix. JAMA 2008; 300(17):2057-2059.
34. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments [Review]. Clin Infect Dis 2006;43(Suppl 4):S173-S177. (Pubitemid 44901884)
35. Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict 2008;17(2):116-120. (Pubitemid 351507728)
36. Fishman MJ, Mee-Lee D, Shulman GD, et al. Supplement to the ASAM Patient Placement Criteria on the Management of Alcohol Use Disorders. Baltimore: Lippincott Williams & Wilkins, 2010.
37. Fleming MF, Davis J, Passik SD. Reported lifetime drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Med 2008;9(8):1098-1106.
38. Gordon AJ, Krumm M, for the Buprenorphine Initiative in the VA (BIV). Buprenorphine Resource Guide, Version 8. Washington: Department of Veterans Affairs, 2008.
39. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal [Review]. Cochrane Database Syst Rev 2006;(2):CD002025.
40. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal [Review]. Cochrane Database Syst Rev 2009;(3):CD002025-pub4.
41. Gunderson EW, Fiellin DA. Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs 2008;22(2):99-111.
42. Han B, Gfroerer JC, Colliver JD, Penne MA. Substance use disorder among older adults in the United States in 2020. Addiction 2009;104(1):88-96.
43. Health Resources and Services Administration. An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care Settings: (1) Demonstration Models and (2) Evaluation and Support Center (HRSA-04-078). Rockville: HIV/AIDS Bureau, Demonstration Project Development and Evaluation Branch, Special Projects of National Significance, 2004. Available at: http://hab.hrsa.gov/abouthab/special/buprenorphine.html. Accessed October 23, 2006.
44. Helm S, Trescot AM, Colson J, Sehgal N, Silverman S. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification [Review]. Pain Physician 2008;11(2):225-235. (Pubitemid 351546233)
45. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70(Suppl 2):S87-S101. (Pubitemid 36556063)
46. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003;70(Suppl):S59-S77. (Pubitemid 36556061)
47. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after Methadone or Buprenorphine exposure. N Engl J Med. 2010;363:2320-2331.
48. Jones HE, Jasinski DR, O'Grady KE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Dependence 2005;79(1):1-10. (Pubitemid 41557119)
49. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abus Treat 2008;35(3):245-259.
50. Joseph H, Stancliff S, Lagrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues [Review]. Mt Sinai J Med 2000;67(5-6):347-364.
51. Kakka J, Hellig M, Sarman I. Buprenorphine andmethadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008;96 (1-2):69-78.
52. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-1413. (Pubitemid 41105554)
53. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-IIIR psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19.